Tundra Space

Tundra Space

Clinical Research Directory

Browse clinical research sites, groups, and studies.

Back to Studies
RECRUITING
NCT05577819
NA

Prevalence and Prediction of ATTR in Ambulatory Patients With HFpEF

Sponsor: Massachusetts General Hospital

View on ClinicalTrials.gov

Summary

Recent studies have shown that transthyretin amyloidosis (ATTR) can sometimes cause a type of heart failure where the pumping function of the heart is normal, also known as Heart Failure with Preserved Ejection Fraction (HFpEF) or diastolic heart failure. In this single center diagnostic study, we will evaluate for ATTR in patients with HFpEF in order to to determine how frequently this occurs and how we can predict which heart failure patients may have TTR amyloidosis. Our goal is to identify amyloidosis in heart failure patients earlier so that they can start treatment.

Official title: Prevalence and Prediction of Transthyretin Amyloidosis in Ambulatory Patients With Heart Failure With Preserved Ejection Fraction

Key Details

Gender

All

Age Range

65 Years - Any

Study Type

INTERVENTIONAL

Enrollment

515

Start Date

2020-10-02

Completion Date

2026-12-31

Last Updated

2024-12-09

Healthy Volunteers

No

Interventions

DIAGNOSTIC_TEST

99mTc-pyrophosphate Scintigraphy

Cardiac Imaging Technique used to diagnose Transthyretin Cardiac Amyloidosis by use of 15 mCi of 99mTC-Pyrophosphate tracer

Locations (1)

Massachusetts General Hospital

Boston, Massachusetts, United States